Bright Angel: New hope against fungal resistance

How Bright Angel's HSP90 inhibitor could block antifungal resistance

Bright Angel is tackling antifungal resistance at its root with inhibitors of Hsp90 and other stress response factors, unlike competitors that are developing compounds against known or new pathways where resistance can still emerge.

Resistance to the three approved classes of antifungal agents -- azoles, polyenes and echinocandins -- is a growing problem, yet most compounds in development tread the same biological pathways as those classes. According to Bright Angel Therapeutics Inc. co-founder and CSO Leah Cowen, fungal and

Read the full 789 word article

User Sign In